Approval · Notice of Compliance 37372 · 2026
ACTEMRA: Notice of Compliance 37372
Issued April 22, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37372
- Date
- April 22, 2026
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a drug substance manufacturing site and drug substance manufacturing process changes
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACTEMRA | Not yet assigned | — |
Medicinal ingredients
- TOCILIZUMAB 80 MG per 4ML
- TOCILIZUMAB 200 MG per 10ML
- TOCILIZUMAB 400 MG per 20ML